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Abstract Rapamycin has been shown to extend lifespan in rodent models, but the effects on metabolic health and
function have been widely debated in both clinical and translational trials. Prior to rapamycin being used as a treatment to
extend both lifespan and healthspan in the human population, it is vital to assess the side effects of the treatment on
metabolic pathways in animal model systems, including a closely related non‐human primate model. In this study, we
found that long‐term treatment of marmoset monkeys with orally‐administered encapsulated rapamycin resulted in no
overall effects on body weight and only a small decrease in fat mass over the first few months of treatment. Rapamycin
treated subjects showed no overall changes in daily activity counts, blood lipids, or significant changes in glucose
metabolism including oral glucose tolerance. Adipose tissue displayed no differences in gene expression of metabolic
markers following treatment, while liver tissue exhibited suppressed G6Pase activity with increased PCK and GPI activity.
Overall, the marmosets revealed only minor metabolic consequences of chronic treatment with rapamycin and this adds to
the growing body of literature that suggests that chronic and/or intermittent rapamycin treatment results in improved
health span and metabolic functioning. The marmosets offer an interesting alternative animal model for future
intervention testing and translational modeling.

INTRODUCTION

disease, cardiovascular disease, and cancer in mouse
models of these pathologies [2-5]. These findings have
led to significant interest in the potential effects of
rapamycin as an anti-aging intervention in humans
particularly because rapamycin is already approved for
use in cancer therapy and as an adjunct immunosuppressive agent for transplant patients.

Rapamycin has been found by multiple laboratories to
extend mouse lifespan even when mice began receiving
rapamycin relatively late in life at 20 months of age, or
roughly the equivalent of 55 human years [1]. In
addition, rapamycin has been shown to delay the onset
of several age-related diseases, including Alzheimer’s
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However, clinical administration of rapamycin has the
potential for several side-effects include hyperlipidemia
and hyperglycemia [6], raising concerns as to the
potential negative impacts of rapamycin exposure in
aged human populations that may have a high
underlying prevalence of obesity- and age-induced
insulin resistance and hyperlipidemia.
However,
results from clinical populations suggests that some side
effects, such as hypertriglyceridemia, may improve over
time and that others may be dose-dependent [6]. The
nature of the human data accumulated thus far paints a
far from complete picture of why and how rapamycin
might affect metabolism and lipid trafficking.
Moreover, these clinical studies have focused on
patients with pre-existing conditions and have largely
utilized
combination
therapies
with
other
immunosupressants or steroids that can cause metabolic
dysfunctions of their own [7]. There have, however,
been no long-term studies of the effects of
monothereapy with rapamycin or its analogs in
populations of otherwise healthy humans. Thus, it is not
clear whether the previously reported metabolic risks of
rapamycin and its analogs are due to this drug directly
or to other confounding factors.

laboratory rodents [14]. Even the timing of or causes of
eating/overeating differ between rodent models and
humans, further complicating this issue [15, 16]. At the
molecular level, there are significant discrepancies
between rodents and humans in alterations of gene
regulation in metabolic dysfunction suggesting there is
little overlap between the two models [17]. Lastly,
many of the complications of metabolic dysfunction
including nephropathy, neuropathy, and cardiac
dysfunction cannot be successfully replicated in single
genetic mouse models of metabolic dysfunction or in
high fat-fed rodents [18]. Thus, a significant question
remains whether the choice of diet (as well as sex of
animals or background genetics) could potentially
complicate the potential for translation [19-21]. An
approach to address whether the effects (and potential
side-effects like metabolic dysfunction) of rapamycin in
otherwise healthy rodents may also be relevant to
humans is to perform such experiments in other
species that are predicted to have similar phenotypic
metabolic regulation as humans. In other words,
studies of rapamycin’s effects in a species more
closely related to humans can inform as to the
generalizability of the rodent findings and issues likely
to impede the general use of rapamycin as an antiaging treatment in humans.

In rodent models, monotherapy with rapamycin has
largely, though not equivocally, been associated with
impairment of glucose metabolism as measured in
glucose tolerance tests. A notable exception is a study
by Fang et al. suggesting that chronic treatment with
rapamycin has a biphasic effect on glucose metabolism
with short-term rapamycin treatment being detrimental
to glucose metabolism whereas long-term (20 wk)
treatment with rapamycin may promote an insulinsensitive state in mice with a transition state in between
[8]. Further examination has revealed that long term
treatment of rapamycin leads to a metabolic switch
resulting in enhanced insulin signaling and better
triglyceride processing [9]. These rodent studies have
largely been performed in animals maintained on a
relatively standardized rodent chow, though there is
evidence that rapamycin has similar effects on both
lifespan and metabolic function in mice fed diets high in
caloric content due to increased levels of sugar and/or
fat [10,11]. Mice given intermittent treatment of
rapamycin and placed on a high fat diet have no gross
changes in metabolic markers, and rapa appears to
prevent weight gain [12]. Combining the intervention
therapies of rapamycin and resveratrol treatment in
mice was found to prevent insulin resistance in mice
being fed a high fat diet and suggests that combination
therapy may be beneficial in a high fat environment
[13]. Human glucose metabolism is regulated by a
complex interaction of genetics and environment
(including diet) that cannot be fully recapitulated in
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The common marmoset (Callithrix jacchus) is a small
monkey with a relatively short lifespan. Both its small
size and associated shorter lifespan make this species a
valuable nonhuman primate model for the study of
aging and chronic disease [22, 23]. Captive marmosets
display many similarities to humans in terms of obesity
and its sequelae. Spontaneous obesity has been
described in multiple captive marmoset colonies that are
socially housed and fed a relatively low fat, high fiber
diet [22, 24-28]. Obesity in marmosets, defined in a
fashion similar to that used in humans, is statistically
associated with increased risk to metabolic dysfunction
and cardiovascular disease [16]. In addition to
displaying evidence of insulin resistance, marmosets at
extremely high weights (over 500 grams) show higher
age-specific mortality rates as adults when compared to
animals of average weight [22]. From 2010-2011, we
conducted a year-long study of daily dosing of a group
of common marmosets with rapamycin. We previously
reported that we were able to maintain circulating blood
levels of rapamycin at 5.2 ng/mL by giving the animals
a dose of eudragit encapsulated rapamycin in yogurt of
1mg/kg/day. Subjects demonstrated a decrease in
mTORC1 after two weeks of treatment. There was no
evidence of clinical anemia, mouth ulcers, lung fibrotic
changes, significant changes in wound healing, or
increased mortality [29]. This report describes a set of
metabolic outcomes from this study.
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RESULTS

difference between control and rapamycin treated
subjects at the end of the study as illustrated in Fig. 1B.
There were no significant differences between controls
and rapamycin treated subjects and no effects of
rapamycin treated subjects over time on body lean
mass.

Body Composition
Rapamycin treated subjects displayed a significant loss
of body fat mass at two months post-dosing while
control subjects displayed a statistically insignificant
change in body fat mass, as illustrated in Fig. 1A
(treatment x time interaction, p < 0.0097; difference in
month 0 and month 2 mean for rapamycin treated
subjects, p < 0.05, Sidak’s multiple comparison test).

Food intake and activity levels
There were no significant differences between controls
and rapamycin treated subjects in food intake at two
months post-dosing. In rapamycin-treated marmosets,
there was a significant increase in food intake at month
5, over the pre-dosing food intake (treatment effect,
F=8.353, p=0.001, Dunnett’s multiple comparison test
significant, p < 0.05, for month 0 versus month 5), as
illustrated in Fig. 2.

Figure 2. Food intake. Daily dry matter intake for months 0‐
12, month 0 is a pre‐dosing measurement. Squares = control
subjects; triangles = rapamycin subjects (mean + SD). *
treatment effect, F=8.353, p=0.001, Dunnett’s multiple
comparison test significant, p < 0.05, for month 0 versus month 5.

Figure 1. Change in fat mass. (A) Change in fat mass at 1 and
2 months, post‐dosing, from pre‐dosing (month 0)
measurement. Squares = control subjects; triangles = rapamycin
subjects (mean + SD); treatment x time interaction, p < 0.0097;
difference in month 0 and month 2 mean for rapamycin treated
subjects, p < 0.05, Sidak’s multiple comparison test. (B) Change
in fat mass from pre‐dosing measurement for months 1‐11 for
rapamycin subjects. * treatment effect, F=5.385, p=0.018,
Dunnett’s multiple comparison test significant, p < 0.05, for
month 0 versus months 2, 3, and 5.

In both control and rapamycin-treated subjects activity
scored as accelerometer counts per hour declined
significantly after the second month of dosing, as
illustrated in Fig. 3, then remained stable over the
remainder of the study. There were no significant
differences between controls and rapamycin treated
subjects. Because both groups were affected, these data
suggest that this decline was a result of habituation to
wearing the harness holding the accelerometer.

The rapamycin treated subjects had significantly
reduced body fat mass in months 2, 3 and 5, after which
their mean fat mass did not differ from the pre-dosing
mean (treatment effect, F=5.385, p=0.018, Dunnett’s
multiple comparison test significant, p < 0.05, for
month 0 versus months 2, 3, and 5), resulting in no
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Lipid and glucose metabolic measures
There were no significant differences between controls
and rapamycin-treated subjects in pre- versus postdosing mean circulating triglyceride concentrations.
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Three measures of glucose metabolic function were
assessed: fasting blood glucose, QuickI index, and
AUC. There were no significant changes in fasting
glucose concentrations as illustrated in Fig. 5A. The
QuickI index, calculated as 1/[log(fasting insulin) +
log(fasting glucose)], is the typical measure reported in
nonhuman primate studies to provide an estimate of
insulin sensitivity, with higher values indicating more
insulin sensitivity. The area under the curve (AUC) for
the glucose tolerance tests represents the relative
glucose excursion caused by a consistent dose of
glucose and is a measure of the efficiency with which
the entire system can remove glucose from the
circulation. As illustrated in Fig. 5D, the mean QuickI
index for the control group was higher than that for the
rapamycin treated group prior to treatment (F=5.396, p
= 0.0453, Sidak’s multiple comparison test, p < 0.05 for
month 0 control vs rapamycin treated), suggesting that
the animals that became the control group were, on
average, more insulin sensitive than those in the group
randomly selected to be treated with rapamycin.
However, the rapamycin-treated group displayed a
reduced QuickI measurement even prior to treatment
that was not altered during these first two months of
dosing as indicated by the lack of a significant
interaction effect. We also found that QuickI did not
differ among rapamycin-treated animals through 8
months of rapamycin treatment as illustrated in Fig. 5C.
There were no differences between control and
rapamycin treated subjects and no interaction effect on
the glucose AUC. There were also no significant
differences in post-dosing average glucose AUC in the
rapamycin treated subjects through 8 months of dosing,
as illustrated in Fig. 5B. Together, these data suggest
limited to no impairment of glucose metabolism in
healthy marmosets treated with daily administration of
rapamycin at doses sufficient to reduce mTOR
signaling.

Fiure 3. Daily activity. Accelerometer counts per hour for
months 2‐13 of dosing. Squares = control subjects; triangles=
rapamycin subjects (mean + SD).

There was, however considerable inter-individual
variation in both baseline triglyceride concentration and
in change over time, as illustrated in Fig. 4. Two of the
rapamycin treated subjects that were borderline
hypertriglyceridemic (476 and 402 mg/dl, with > 400
mg/dl defined as hypertriglyceridemic, [24] before
dosing, displayed dramatic increases in circulating
triglyceride concentration at month 2 (702 and 1,359
mg/dl); however, their triglyceride concentrations then
varied considerably over the next 7 months. There was
no consistent hypertriglyceridemia caused
by
rapamycin among subjects who began with normal
circulating triglyceride concentrations There were two
subjects (one control and one rapamycin treated) that
displayed severe hypertriglycerimedia before dosing
(603 and 1,611 mg/dl respectively).
They both
remained hypertriglyceridemic through the study.

Assessment of molecular effects
The long-term administration of rapamycin in rodents
has been associated with hyperglycemia caused in part
by increased gluconeogenesis [27-29]. In the liver of
rapamycin treated animals, we found significant
upregulation of the expression of phosphoenolpyruvate
carboxykinase (PCK1), indicative of altered gluconeogenic capacity. Surprisingly, we found that glucose 6
phosphatase expression in rapamycin treated animals
was significantly reduced (Fig. 6). Rapamycin did not
alter the expression of other markers of
gluconeogenesis. The lack of a consistent alteration in
the expression of gluconeogenic effectors may explain
why rapamycin-treated marmosets showed no
significant change in fasting blood glucose levels.

Figure 4. Circulating triglyceride. Circulating triglyceride
concentrations for each rapamycin subject for months 0‐6,
month 0 is a pre‐dosing measurement. The solid horizontal line
represents the previously established cut‐off point for normal
triglyceride concentrations in this species.
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Figure 5. Metabolic measures. (A) Fasting glucose concentration for months 0‐8 for rapamycin subjects, month
0 is a pre‐dosing measurement. (B) Glucose area under the curve (AUC) for months 0‐8 for rapamycin subjects. (C)
QuickI index for rapamycin subjects for months 0‐8. (D) QuickI index ‐ 1/[log(fasting insulin) + log(fasting glucose)]
for months 0 and 2 of dosing, *(F=5.396, p = 0.0453, Sidak’s multiple comparison test, p < 0.05 for month 0 control
vs rapamycin treated). For all panels squares = control subjects; triangles = rapamycin subjects (mean + SD).

Because rapamycin modulated fat content of marmosets
in the early periods of treatment, we assessed the
potential modulation of effectors of lipolysis/lipogenesis in adipose. In visceral adipose samples, we found no
significant effects on the phosphorylation or expression
of any of these markers, suggesting little effect of
rapamycin. However, at the time of sacrifice,
rapamycin-treated marmosets were not significantly
leaner than control animals. Due to limitations of the
design of this study, we could not determine whether
these effectors were altered by rapamycin at earlier time
points when fat mass was reduced by treatment (Fig. 1B).
Figure 6. Immunoblot results. Immunoblot results for the following:
adipose triglyceride lipase (ATGL), pyruvate carboxylase (PCB), glucose‐6‐
phosphatase α (G6Pase), glucose‐6‐phosphate isomerase (GPI), peroxisome
proliferator‐activated receptor γ (PPARγ), phospho‐pyruvate dehydrogenase
kinase (p‐PDK1), pyruvate dehydrogenase kinase (PDK1), phosphoenol‐
pyruvate carboxykinase 1 (PCK1), sterol regulatory element‐binding protein 1
(SREBP1) corrected by actin. A. Adipose tissue collected at sacrifice following
14 monthsDISCUSSION
of rapamycin (black) or control dosing (grey) (mean + SE) B. Liver
tissue collected at sacrifice following 14 months of rapamycin (black) or
control dosing (grey) (mean + SE) *indicates significance p<0.05.
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DISCUSSION

animals altered caloric intake in response to the fat mass
loss [32].

Prior to assessing the effectiveness of rapamycin as an
anti-aging treatment in humans, it is first necessary to
elucidate the potential effects on long term health
outcomes. In particular, there has been a great deal of
controversy and inconsistent results in the clinical
studies of rapamycin, which have highlighted the
potential increased risk for metabolic defects such as
hyperlipidemia and hyperglycemia that are consistent
with increasing risk of cardiovascular disease and type 2
diabetes [30]. However, the effects of this drug on
relatively healthy humans are largely unknown. A
recent short term study (6 weeks) of elderly patients
given doses of a rapamycin analog found few side
effects significant from placebo control subjects and
reported a significant increase in serological response to
flu vaccination, however, this study did not examine
any markers of metabolic health in these subjects during
treatment [31].
In order to assess potential
consequences of long term rapamycin treatment on
primate metabolic health we tested the effects of
rapamycin on a group of healthy, aged, non-human
primates, the common marmoset. We previously
reported the ability to reliably and routinely dose
socially housed marmoset monkeys with yogurt
mixtures containing eudragit encapsulated rapamycin
[29]. Dosing with 0.4 mg/day resulted in average blood
rapamycin levels of 5.2 ng/mL, which is well within the
range found in studies of other model species, and
humans [1-5]. Further, we previously reported evidence
of suppressed phospho-rpS6 in PBMC samples of
rapamycin subjects suggesting down-regulation in
mTORC1. In this study we reported several markers
that suggest that chronic oral dosing with eudragitencapsulated rapamycin has little impact on the
metabolic status of marmosets.

One of the major reported risks of rapamycin
administration clinically is the development of newonset type 2 diabetes as shown in clinical studies of
kidney transplant patients treated with rapamycin
analogs [33, 34]. However, the interpretation of these
data is complicated by several factors including the
impaired health status of the subjects and the use of
combination therapies using additional drugs that are
known to cause metabolic impairment on their own.
Recent clinical studies of kidney transplant patients
suggest that Tacrolimus rather than Sirolimus may be
the leading cause of new onset diabetes within 10 weeks
of treatment, however all research suggests that
continued examination of monotherapies are needed to
elucidate the side effects of each immunosuppressant
[35, 36]. In rodents, the chronic administration of
rapamycin as a mono-therapy has often been shown to
impair glucose metabolism. For example, both inbred
and genetically heterogeneous mouse strains develop
glucose intolerance with oral administration of
encapsulated rapamycin [11, 37, 38]. In inbred
C57BL/6 mice, but not genetically heterogeneous mice,
rapamycin is also associated with the development of
insulin resistance.
Interestingly, these effects of
rapamycin on metabolism are dependent on both dose
of rapamycin and sex of subjects [38] and do not appear
to be permanent alterations as the metabolic defects can
be reversed by ending rapamycin treatment [11].
Similarly, rapamycin treatment to normoglycemic, prediabetic P. obesus treated with rapamycin display
heightened hyperglycemia and increased insulin
resistance in part by reducing pancreatic β-cell function.
In this rodent model it was suggested that rapamycin
exacerbated the pre-existing diabetic symptoms and
metabolic disorder in high risk animals [39].
Alternatively the effect of rapamycin is thought to
mimic the metabolic changes associated with starvation
diabetes or Type 0 diabetes [40, 41, 42]; which is often
thought to be a positive, adaptive form of metabolic
changes associated with enhanced metabolic efficiency
and decreased risk of true diabetes. Evidence of
enhanced insulin signaling following long term rapa [9],
and intermittent rapa [11], as well as little evidence for
detrimental mitochondrial function following rapamycin
[42], supports the hypothesis that rapamycin may in fact
be inducing changes similar to starvation diabetes [13,
40-42]. Interestingly, in our current study we found no
evidence that rapamycin negatively impairs glucose
metabolism in marmosets. One possible interpretation
of these findings could be that rapamycin treatment
might negatively and significantly affect only subjects
that are predisposed to metabolic disease. This also

Many have proposed that rapamycin is a mimic of
calorie restriction which is the gold-standard for antiaging intervention resulting in both extended life span
and health span in many rodent models. Rapamycin has
been shown to suppress mTOR activity, potentially
decrease weight and fat mass, and extend healthspan
and life span in a similar manner as calorie restriction
[1-4]. In marmosets we demonstrated no overall change
in body weight while being treated with rapamycin, but
the marmosets did have significant loss of body fat.
However, the loss of body fat stabilized at
approximately five months of treatment and this time
point was associated with an increase in food intake of
rapamycin subjects. While we are unable to elucidate
the underlying mechanisms for the sudden shift in
dietary intake at 5 months of dosing, it is interesting to
consider the possibility that the rapamycin-dosed
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might explain some of the slight differences in
rapamycin’s effect on glucose metabolic dysfunction in
C57BL/6 but not genetically mixed mice. Another
possible explanation could be the length of treatment
utilized here. Recent studies have suggested a bi-phasic
effect of rapamycin on glucose metabolism, with longterm administration of rapamycin to mice associated
with increased, rather than reduced insulin sensitivity
[8, 9, 44]. However, others have shown rapamycin in
eudragit-encapsulated form (as we used in this study)
does not show this bi-phasic effect, but rather
continuously impairs glucose metabolism in mice
[11,37]. In part, the metabolic impairments of
rapamycin are thought to be due to inhibition of
mTORC2 rather than mTORC1 [45]; while we
previously showed that this rapamycin dose was
sufficient to inhibit mTORC1 [29], it may not be
sufficient to inhibit mTORC2 signaling in the marmoset
and thus minimize the presumed metabolic defects of
rapamycin treatment.

ween rapamycin-treated and control marmosets and we
found no evidence for differences in lipolysis or
lipogenesis in adipose tissue collected at the end of this
study. Interestingly, this change coincided with a
significant increase in food consumption among the
rapamycin-treated marmosets. This alteration could
represent a compensatory effect for the long-term
inhibition of mTOR signaling. Further temporal studies
regarding the effect of rapamycin in this model will be
necessary to address this possibility.
Treatment with rapamycin as an intervention in the
aging process for humans offers many possibilities but
some studies have reported deleterious side effects that
raise concern regarding the efficacy of this treatment.
This study represents the first to examine the metabolic
consequences of rapamycin dosing in healthy nonhuman primates. We have reported here evidence that
long term rapamycin treatment at a dose that has been
used in previous studies and reduces mTOR signaling in
marmosets [29] does not result in notable negative sideeffects on metabolic function in healthy marmosets. We
believe that marmosets offer a unique non-human
primate model that will allow detailed evaluation of the
effect of potential anti-aging treatments on primate
metabolic function, dietary intake, and activity
patterning.

The increased risk of hyperglycemia with rapamycin
treatment has been attributed to increased hepatic
gluconeogenesis in rodent studies. In both mice and rats,
rapamycin treatment significantly increases hepatic
glucose production following injection with pyruvate and
increases the expression of the gluconeogenic effectors
like PCK1 and G6Pase [45, 46]. In this study, we also
confirmed that a significant increase in PCK1 with
rapamycin treatment, but paradoxically, found a
significant decrease in G6Pase. While the rise in PCK1
would be consistent with increased gluconeogenesis, the
decrease in G6Pase might be interpreted as inhibiting this
process. It is not clear why rapamycin treatment has this
contrasting effect in marmosets, but this might explain
why marmosets did not display hyperglycemia with this
treatment.

MATERIALS AND METHODS
Subjects. The subjects for this study were common
marmosets (Callithrix jacchus) housed at the Southwest
National Primate Research Center. Basic husbandry and
housing for this colony have been described previously
[51]. Thirteen subjects between the ages of 7.1 and 9.1
years were housed as female-vasectomized male pairs.
Four pairs received daily oral dosing of 1.0 mg/kg/day
(0.40 mg/day) rapamycin in a yogurt vehicle via syringe
for 14 months as described [29]. Two pairs (5 subjects,
one male died mid-way through the study and was
replaced with another male) received daily doses of
empty eudragit capsules in yogurt as control.
Throughout the long term dosing regimen several
markers of metabolic health were assessed.

In addition to its well-known roles in cell survival and
growth, recent studies have linked the mTOR signaling
pathway with the regulation of lipid metabolism [47].
However, the direct effects of rapamycin on lipid
metabolism have often been contradictory in published
reports. For example, rapamycin has been reported to
both improve and impair fatty acid oxidation in skeletal
muscle cell lines [44, 48]. Reports regarding
rapamycin’s effects on lipid utilization in vivo in
rodents are similarly inconsistent; rapamycin has been
reported to decrease, increase or not effect fat
accumulation among several different studies [1, 11, 37,
38, 49, 50]. Here, we found that rapamycin significantly
reduced fat mass in marmosets at early time points in
our treatment regime. However, after approximately 5
months of treatment, fat mass no longer differed bet-
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Body composition: Marmoset lean and fat mass was
assessed monthly via quantitative magnetic resonance
(QMR) imaging using an Echo MRI unit [26].
Unsedated animals were placed in a plastic tube which
was then inserted into the magnetic chamber with scans
taking less than 2 minutes on average for each animal.
Animals were weighed biweekly throughout the project
by placing a scale within the cage and rewarding the
animal’s for maintaining position on the scale.
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Caloric intake. Subjects participated in a 2 day food
intake trial once per month for the length of the trial
[28]. For these trials the subjects were separated from
each other within the cage and fed their daily base diet
consisting of two feed types from Harlan Teklad and
Purina. Samples of each diet were taken from each
prepared batch, frozen and stored until analysis. Diet
fed to the subjects was weighed prior to feeding. After
24 hours all remaining food was removed and weighed,
and fresh food was weighed and fed. After 48 hours all
remaining food was removed and weighed and the
subjects were returned to normal housing and feeding
schedule. Samples were dried and dry weight
consumption and caloric consumption was calculated
and averaged over the 48 hour period.

animals were then dosed orally with a 40% dextrose
solution receiving a calculated glucose dose equal to
0.5% of their current body weight. Subjects remained
in the restraint for a 15 and 30 minute post dose blood
sample drawn from the tail vein via an EDTA coated
butterfly needle. Subjects were removed from the
restraint device following the 30 minute sample and
placed in a transport box until the 60 minute sample,
and this was repeated for the 120 minute sample. The
15, 60 and 120 minute samples were glucometer reads
only. For the 30 minute sample 0.5 ml of blood was
collected for further analysis. Following the 120 minute
bleed the animals were returned to their home cage and
fed. The 0 and 30 minute samples were spun and frozen
until shipment to Wisconsin for insulin assay analysis.

Activity. Daily activity patterns were assessed with the
Mini actiwatch (CamNtech) which were placed in a
marmoset pouch (Lomar) on a ferret harness (Petco).
Subjects were gradually habituated to the ferret
harnesses over the course of three weeks, increasing
time in the harness incrementally throughout training
until 24 hours in the harness had been achieved. The
miniwatches are data loggers that batch data in 15
second epochs. For these trials animals were separated
from each other within the cage and placed in harnesses
with the actiwatch in the pouch secured across the back
of the animal. Animals remained in the harness for 48
hours of data collection during which normal husbandry
and feeding continued. At the end of the trial the
animals were captured in transfer boxes and the
harnesses were removed. Data was downloaded from
the device. The activity counts from the first 15 minutes
and last 15 minutes of the collection were removed
from analysis as these represented handling and cage
manipulation.

Immunoblots. Total protein extracts were isolated from
liver and visceral fat tissue that had been snapped
frozen in liquid nitrogen after sacrifice and stored at 80°C until use. Protein extracts were homogenized in
RIPA buffer with additional protease and phosphatase
inhibitors (Thermo Scientific, Rockford, IL, USA),
centrifuged at 14,000g at 4°C for 15 minutes, and then
stored at -80°C until needed. Equal amounts of protein
samples were separated electrophoretically by SDSPAGE and then transferred to polyvinylidene difluoride
membrane (Millipore, Billerica, MA, USA). Primary
antibodies and their sources used in this study: adipose
triglyceride lipase (ATGL), pyruvate carboxylase
(PCB), glucose-6-phosphatase α (G6Pase), glucose-6phosphate isomerase (GPI), and actin from Santa Cruz
(Santa Cruz CA), peroxisome proliferator-activated
receptor γ (PPARγ), phospho-pyruvate dehydrogenase
kinase (p-PDK1), pyruvate dehydrogenase kinase
(PDK1), phosphoenolpyruvate carboxykinase 1 (PCK1)
from Cell Signaling (Beverly MA), sterol regulatory
element-binding protein 1 (SREBP1) from Abcam
(Cambridge MA) and deptor from Millipore with all
alkaline phosphatase-conjugated secondary antibodies
(anti-rabbit and anti-mouse) from Santa Cruz. Protein
bands on immunoblots were detected using ECL
reagent and analyzed using ImageJ.

Blood chemistry. Each month animals were fasted
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